# Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

> **NCT06581432** · PHASE2 · RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 430 (estimated)

## Conditions studied

- Solid Tumours

## Interventions

- **DRUG:** Zongertinib

## Key facts

- **NCT ID:** NCT06581432
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-11
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-29
- **Target enrollment:** 430 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06581432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06581432, "Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06581432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*